Glenmark launches Prasugrel for the first time in India

Press ReleaseFor Immediate DisseminationGlenmark launches Prasugrel for the first time in India• A revolutionary new antiplatelet drug for the management of AcuteCoronary Syndrome with PCI• Estimated market size at Rs. 300 croresMumbai April 29, 2010 : Glenmark Pharmaceuticals Limited has launched for the first timein India - ‘Prasugrel’ a revolutionary new anti-platelet drug for the management of AcuteCoronary Syndrome with PCI (Percutaneous Coronary Intervention). PCI is better known asthe angioplasty procedure which normally includes the placement of a stent to keep the arteryopen.Prasugrel will be marketed in India by Glenmark as ‘Aplet’. It is an oral anti-plateletmedicine specifically for patients who have undergone an angioplasty procedure to open up ablocked heart artery after experiencing a heart attack or heart-related chest pain at rest(unstable angina) - Both these medical conditions are known as Acute Coronary Syndrome.Prasugrel (Aplet) offers an effective alternative to current oral anti-platelet drugs which haveseveral limitations including slow onset of action, interpatient variability and possibility ofpoor or no response in some patient’s especially those who are diabetic. The estimatedmarket size for this product is Rs. 300 crores.Commenting on this development, Mr. Rajeev Sibal, Vice President - India Formulations,Glenmark Pharmaceuticals Limited mentions “With the introduction of Aplet, Glenmark hasprovided a superior anti-platelet medicine for the management of patients who have AcuteCoronary Syndrome with PCI. He further added “Glenmark will continue its efforts ofintroducing first to market products across therapeutic categories in the country”Clinical studies have shown that treatment with Prasugrel helps to reduce the risk of a futureheart-related event, such as a heart attack or stent clot, in patients who had an ACS event thatwas treated with angioplasty.1

About Glenmark Pharmaceuticals Ltd.Glenmark Pharmaceuticals Ltd. (GPL) is a research-driven, global, integrated pharmaceutical companyheadquartered at Mumbai, India. It is a leading player in the discovery of new molecules both NCEs (newchemical entity) and NBEs (new biological entity). Glenmark has eight molecules in various stages ofclinical development and is primarily focused in the areas of Inflammation [asthma/COPD, rheumatoidarthritis etc.], Metabolic Disorders [diabetes, obesity, etc.] and Pain [neuropathic pain and inflammatorypain]. The company has a significant presence in branded generics markets across emerging economiesincluding India. GPL along with its subsidiary has twelve manufacturing facilities in four countries andhas five R&D centres.####For further information, please contact:Jason D’SouzaGlenmark, Mumbai, IndiaTel: [+91 22] 40189919 / 40189993 Email : media@glenmarkpharma.com2